Previous close | 4.8000 |
Open | 4.8000 |
Bid | 4.4000 |
Ask | 4.9000 |
Strike | 7.50 |
Expiry date | 2024-07-19 |
Day's range | 4.8000 - 4.8000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
REDWOOD CITY, Calif. & BOSTON, June 24, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic "off-the-shelf" gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ c
We recently compiled the list of the 7 Best Halal Stocks To Buy Now (Debt Free) according to the hedge funds using the latest sentiment data. In this article, we are going to take a look at where Adicet Bio, Inc. (NASDAQ:ACET) stands against the other halal debt free stocks. Halal Investing: Debt-Free Stocks, Islamic […]
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...